In 1892, Louis Vaquez of Paris described a patient with cyanoticpolycythemia; the autopsy disclosed massive enlargement of thespleen and liver. In 1903, William Osler, then at Johns HopkinsHospital, reported on four patients with polycythemia, two ofwhom had splenomegaly. He gave credit to Vaquez for the earlierdescription, and the disorder was later named Osler–Vaquezdisease, though today it is usually referred to as polycythemiavera.
In 1951, William Dameshek drew attention to the relationshipsamong polycythemia vera, idiopathic myelofibrosis, and essentialthrombocythemia and proposed that these diseases, as well aschronic myeloid leukemia and erythroleukemia, should . . . [Full Text of this Article]
Source Information
Dr. Goldman is a Fogarty Scholar in the Hematology Branch of the National Heart, Lung, and Blood Institute, Bethesda, Md.
This article has been cited by other articles:
Schafer, A. I.
(2006). Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood
107: 4214-4222
[Abstract][Full Text]
Frohling, S., Lipka, D. B., Kayser, S., Scholl, C., Schlenk, R. F., Dohner, H., Gilliland, D. G., Levine, R. L., Dohner, K.
(2006). Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Blood
107: 1242-1243
[Full Text]
Previous
